Current status of the IRR and testing availability
As the pandemic has worn on, testing supply deployment processes by the IRR have become more mature, and many of these hurdles have been overcome. The FDA has granted EUA to many companies supplying reagents and test kits; and approved some alternative reagents and tests if those are depleted. More data than ever before is available about accuracy of testing, and turnaround times are decreasing – which is all great news for patients.
The IRR has never met a challenge as big as COVID-19 and has certainly been through trial by fire.
The IRR has never met a challenge as big as COVID-19 and has certainly been through trial by fire. Important lessons have been learned about scaling testing quickly, and one can only hope this will lead to improved future protocols.